A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab Vedotin
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 10 Sep 2024 Planned End Date changed from 1 Sep 2025 to 1 Mar 2026.
- 10 Sep 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Mar 2025.
- 12 Dec 2023 Results (n=19; as of 27 Jul 2023) reporting final safety, efficacy and correlative analysis presented at the 65th American Society of Hematology Annual Meeting and Exposition